Table 1.
Baseline characteristics.
| PLHIV (n = 208) | Healthy controls (n = 56) | |
|---|---|---|
| Sex (% Female) | 17 (8.2) | 22 (39.2)* |
| Age (years, median [IQR]) | 52.0 [45.8, 59.0] | 30.0 [25.8–53.0]* |
| BMI (median [IQR]) | 24.1 [22.0, 26.0] | 23.8 [21.5–25.6] |
| HIV infection duration (years, median [IQR]) | 8.5 [5.0, 14.2] | |
| Way of transmission (%) | ||
| Heterosexual | 8 (3.8) | |
| IDU | 3 (1.4) | |
| MSM | 158 (76.0) | |
| Other/unknown | 39 (18.8) | |
| CD4 nadir (median [IQR]) | 250.0 [135.0, 362.5] | |
| CD4 count (median [IQR]) | 660.0 [480.0, 812.5] | |
| Undetectable HIV load, n (%) | 208 (100) | |
| CD4/CD8 ratio (median [IQR]) | 0.8 [0.6, 1.1] | |
| cART duration (years; median [IQR]) | 6.6 [4.1, 11.8] | |
| cART regimen | ||
| NRTI-use (%) | 200 (96.2) | |
| NtRTI-use (%) | 97 (46.6) | |
| NNRTI-use (%) | 61 (29.3) | |
| PI-use (%) | 32 (15.4) | |
| Maraviroc-use (%) | 3 (1.4) | |
| INSTI-use (%) | 140 (67.3) | |
| ABC (%) | 93 (44.7) | |
| DTG (%) | 86 (41.3) | |
| EVG (%) | 15 (7.2) | |
| RAL (%) | 38 (18.3) | |
| Smoking (%) | 59 (28.4) | |
| Pack years (median [IQR]) | 13.8 [0.0, 28.0] | |
| Hypercholesterolemia (%) | 56 (26.9) | |
| Hypertension (%) | 40 (19.2) | |
| Diabetes Mellitus (%) | 9 (4.3) | |
| No cardiovascular risk factors (%) | 50 (24.0) | |
| Statins (%) | 56 (26.9) | |
| Aspirin (%) | 18 (8.7) | |
| Metformin (%) | 9 (4.3) | |
BMI body mass index, cART combination antiretroviral therapy, NRTI nucleoside reverse transcriptase inhibitor, NtRTI nucleotide reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, INSTI integrase inhibitor, ABC abacavir, DTG dolutegravir, EVG elvitegravir, RAL raltegravir.
*Significantly different between cohorts.